WE SEE YOU

At Intercept, our work is motivated by our desire to help patients and families who struggle with chronic liver diseases and need better treatment options.

Scientific Presentations

Scientific presentations for in-depth clinical information

  1. Farnesoid X receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial (Neuschwander-Tetri, et al, AASLD November 8, 2014)
  2. Obeticholic Acid, a Farnesoid X Receptor agonist, reduces bile acid synthesis in patients with Primary Bile Acid Diarrhea (Walters, et al, DDW May 6, 2014)
  3. The effects of Obeticholic Acid, a Farnesoid X Receptor agonist, in patients with chronic diarrhea secondary to Crohn’s ileal disease (Walters, et al, DDW May 6, 2014)
  4. The First Primary Biliary Cirrhosis (PBC) Phase 3 Trial in Two Decades – an International Study of the FXR Agonist Obeticholic Acid in PBC Patients (Nevens, et al, EASL, April 12, 2014)
  5. The FXR Agonist Obeticholic Acid Improves a Transplant-Free Survival-Proven Biochemical Response Criterion In Placebo Controlled Primary Biliary Cirrhosis Studies (Luketic, et al, EASL, April 10, 2014)
  6. Obeticholic Acid, A Farnesoid-X Receptor Agonist, Reduces Bacterial Translocation and Restores Intestinal Permeability In A Rat Model Of Cholestatic Liver Disease (Verbeke, et al, EASL, April 10, 2014)
  7. Long-Term Treatment of Primary Biliary Cirrhosis with the FXR Agonist Obeticholic Acid Shows Durable Efficacy (Kowdley, et al, EASL, April 10, 2014)
  8. Defining Optimal Laboratory Response Criteria in UDCA Treated Primary Biliary Cirrhosis. Results of an International Multicenter Long-term Follow-up Study (Lammers, et al, AASLD, Nov 3, 2013)
  9. Validation of Alkaline Phosphatase and Bilirubin Values as a Surrogate Endpoint in Primary Biliary Cirrhosis – an International, Collaborative Study (Lammers, et al, AASLD, Nov 3, 2013)
  10. Satellite Symposia Presented for attendees of the 64th AASLD Annual Meeting: Novel Therapeutic Targets in PBC, PSC, & NASH: Translating Today’s Knowledge into Tomorrow’s Practice (November 3, 2013 – 6:30PM, Washington D.C.)
  11. Primary Biliary Cirrhosis: Genetics, Pathogenesis and Therapy of a Prototypic Autoimmune Disease (Shapiro, International Congress of Immunology 2013, August 25, 2013)
  12. G Protein Coupled Receptor TGR5 Activation Prevents Diabetic Kidney Disease in db/db Mice and in Human Podocyte Cells (Levi, et al, ADA, June 22, 2013)
  13. Dual Activation of FXR and TGR5 Protects from Diabetic Nephropathy and Retinopathy in Mouse Model of Type 1 Diabetes (Wang, et al, ADA, June 22, 2013)
  14. A New Therapy for Chronic Diarrhea? A Proof of Concept Study of the FXR Agonist Obeticholic Acid in Patients with Primary Bile Acid Diarrhea (Walters, et al, DDW, May 2013)
  15. Relative potencies of bile acids in inducing Fibroblast Growth Factor 19 (FGF19) in the human ileum (Kennie, et al, DDW, May 2013)
  16. Alkaline Phosphatase Values Are A Surrogate Marker in Prediction of Transplant Free Survival in Patients with PBC – An International, Collaborative Analysis (Lammers, et al, EASL April 26, 2013)
  17. The Development of Drugs Interacting with Bile Acid Receptors (Adorini, EASL, April 26, 2013)
  18. Effect of the FXR Agonist Obeticholic Acid on Portal Pressure in Alcoholic Cirrhosis: A Phase 2 Proof of Concept Study (Mookerjee, et al, AASLD, Nov. 12, 2012)
  19. Long-Term (LT) Therapy of a Farnesoid X Receptor (FXR) Agonist Obeticholic Acid (OCA) Maintains Biochemical Response in Primary Biliary Cirrhosis (PBC) (Hirschfield, et al, EASL, April 20, 2012)
  20. A Long-Term Safety Extension Trial of the Farnesoid X Receptor Agonist Obeticholic Acid and UDCA in Primary Biliary Cirrhosis (Hirschfield, et al, AASLD, Nov. 7, 2011)
  21. AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID AS MONOTHERAPY IN PBC (Kowdley, et al, AASLD, Nov. 5, 2011)
  22. Farnesoid-X Receptor Agonists: a New Class of Drugs for the Treatment of PBC ? An International Study Evaluating the Addition of Obeticholic Acid (INT-747) to Ursodeoxycholic Acid An International Study (Mason, et al, AASLD, Oct. 31, 2010)
  23. A New Therapy for Nonalcoholic Fatty Liver Disease and Diabetes? INT-747 the First FXR Hepatic Therapeutic Study (Sanyal, et al, AASLD, Nov. 2, 2009)
  24. Farnesoid-X Receptor Agonists: a New Therapeutic Class for Diabetes and Fatty Liver Disease? The First FXR Therapeutic Study in Diabetes (Mudaliar, et al, ADA, June 2009)

You are now leaving interceptpharma.com


You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Intercept provides this link as a service to its website visitors. Intercept is not responsible for the content or the privacy policy of any third party websites.

Close this window to return to Intercept Pharma’s site or click ‘Continue’ to proceed. 

You are now being redirected to Intercept's job application site, hosted by a third party.